Table 4.

Modulation of Metaplasia Index (MI) from Baseline to 3 Months by Treatment Arm at Each Dose Level, by Smoking Status^#

Smoking status	Treatment	Variable	N	Mean	Std Dev	Minimum	Median	Maximum
FORMER	CCX, Dose 0	MI0	8	6.25	8.63	0.00	0.00	16.67
		MI3	8	6.25	12.40	0.00	0.00	33.33
		MI30	8	0.00	12.60	−16.67	0.00	16.67
	CCX, Dose +1	MI0	7	4.76	8.13	0.00	0.00	16.67
		MI3	7	0.00	0.00	0.00	0.00	0.00
		MI30	7	−4.76	8.13	−16.67	0.00	0.00
	Placebo	MI0	13	5.13	10.51	0.00	0.00	33.33
		MI3	13	1.28	4.62	0.00	0.00	16.67
		MI30	13	−3.85	12.08	−33.33	0.00	16.67
CURRENT	CCX, Dose 0	MI0	25	15.00	21.97	0.00	0.00	66.67
		MI3	25	16.13	18.95	0.00	16.67	66.67
		MI30	25	1.13	14.87	−33.33	0.00	33.33
	CCX, Dose +1	MI0	29	12.87	14.93	0.00	16.67	50.00
		MI3	29	15.92	17.88	0.00	16.67	66.67
		MI30	29	3.05	18.44	−33.33	0.00	33.33
	Placebo	MI0	44	15.45	23.18	0.00	0.00	83.33
		MI3	44	16.06	22.45	0.00	8.33	100.00
		MI30	44	0.61	22.43	−50.00	0.00	66.67

CCX, Dose 0; low-dose celecoxib

CCX, Dose +1; high-dose celecoxib

MI₀; metaplasia index baseline

MI₃; metaplasia index at 3 months

MI₃₀; metaplasia index difference (MI₃ – MI₀)

^#one patient did not have a 3-month metaplasia index reading from the biopsy